Evidence map›Paper›PMID 33327780›Full record

ReviewExperimental biology and medicine (Maywood, N.J.)2021

Immunomodulatory effects of mesenchymal stem cells for the treatment of cardiac allograft rejection.

Zhichao Wu, Jialiang Liang, Wei Huang, Lin Jiang, Christian Paul, Xiang Gao, Perwez Alam, Onur Kanisicak, Meifeng Xu, Yigang Wang

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Experimental biology and medicine (Maywood, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zhichao WuDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Jialiang LiangDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Wei HuangDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Lin JiangDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Christian PaulDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Xiang GaoDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Perwez AlamDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Onur KanisicakDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Meifeng XuDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Yigang WangDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.ORCID 0000-0002-0872-1860
University of Cincinnati Medical Center · US

Funding

The therapeutic potential of smarter exosomes derived from engineered MSCs on Alzheimer's diseaseR01HL140962 · NHLBI · UNIVERSITY OF CINCINNATI · PI LIU, MIN, XU, MEIFENG · 2018 to 2021
$2.4M
Regulators of extracellular matrix production during cardiac development and diseaseR01HL148598 · NHLBI · UNIVERSITY OF CINCINNATI · PI KANISICAK, ONUR · 2020 to 2024
$2.0M
Autologous Cardiomyocytes from Masseter Muscles to Repair Myocardial Infarction (MI)R01HL136025 · NHLBI · UNIVERSITY OF CINCINNATI · PI DAVIDSON, W SEAN, WANG, YIGANG · 2017 to 2020
$1.8M
IGF-2R is a new therapeutic target for cardiac ischemia-reperfusion injuryR01HL143490 · NHLBI · UNIVERSITY OF CINCINNATI · PI WANG, YIGANG · 2019 to 2022
$1.6M
NHLBI NIH HHS R01 HL136025NHLBI NIH HHS R01 HL140962NHLBI NIH HHS R01 HL143490NHLBI NIH HHS R01 HL148598
6 · The paper itself

Abstract

Heart transplantation continues to be the gold standard clinical intervention to treat patients with end-stage heart failure. However, there are major complications associated with this surgical procedure that reduce the survival prognosis of heart transplant patients, including allograft rejection, malignancies, infections, and other complications that arise from the use of broad-spectrum immunosuppression drugs. Recent studies have demonstrated the use of mesenchymal stem cells (MSCs) against allotransplantation rejection in both

Indexed as

Heart TransplantationMesenchymal Stem Cell TransplantationAllograftsAnimalsGraft RejectionHumansImmunosuppression TherapyMesenchymal Stem Cellsheart transplantationimmunological toleranceimmunomodulationMesenchymal stem cellsrejection

Identifiers

PMID33327780
PMCPMC8719033
OpenAlexW3112338210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.